Related Experiment Videos
Interaction between fluconazole and midazolam in intensive care patients
J Ahonen1, K T Olkkola, A Takala
1Department of Anaesthesia, University of Helsinki, Finland.
Acta Anaesthesiologica Scandinavica
|May 26, 1999
Summary
Fluconazole increases midazolam levels in intensive care unit (ICU) patients by inhibiting CYP3A4 enzymes. Clinicians should consider reducing midazolam infusion rates when co-administered with fluconazole.
Area of Science:
- Pharmacology
- Intensive Care Medicine
- Drug Metabolism
Background:
- Midazolam is a common sedative in ICUs, metabolized by CYP3A4.
- Fluconazole, an antifungal, inhibits CYP3A4-mediated drug metabolism.
- Co-administration of fluconazole and midazolam may alter midazolam pharmacokinetics in critically ill patients.
Purpose of the Study:
- To investigate the effect of fluconazole on midazolam plasma concentrations in mechanically ventilated ICU patients.
- To assess the impact of fluconazole on midazolam metabolism and sedation levels.
Main Methods:
- Ten mechanically ventilated ICU patients on stable midazolam infusions were studied.
- Fluconazole was administered according to standard protocols.
- Plasma concentrations of midazolam and its metabolites were measured over 48 hours.
Main Results:
- Midazolam concentrations significantly increased (up to 4-fold) after initiating fluconazole.
- The increase in midazolam levels was more pronounced in patients with renal failure.
- The ratio of active metabolite (alpha-hydroxymidazolam) to midazolam decreased over time.
Conclusions:
- Fluconazole significantly elevates midazolam levels in ICU patients.
- Reduced midazolam infusion rates may be necessary to avoid over-sedation.
- Monitoring sedation levels is crucial when co-administering these drugs.